From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, the Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about the coming trend of penalizing unhealthy employees, the importance of drug branding, the avian flu outbreak, one stock investors need to watch, and more.

In the following segment, health-care analyst David Williamson discusses the week's biggest movers and shakers, including a trio of stocks receiving the FDA's new "breakthrough" designation. Watch and find out what it means for investors.

Max Macaluso, Ph.D., has no position in any stocks mentioned. David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.

The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.